Logo
    Search

    Podcast Summary

    • Understanding Brain Disorders with Living Human Brain CellsBrain organoids, a new technology, allow us to study human brain development and disorders using living human brain cells in a dish, bringing us closer to a molecular understanding and potential treatments.

      Our current understanding of brain disorders is limited due to the lack of access to living human brain tissue. Traditional methods like genetic studies, autopsies, and primates have their limitations. A new technology called brain organoids offers a solution by allowing us to study the human brain, both its development and disorders, with living human brain cells in a dish for the first time. Brain organoids are not mini brains or brains in a dish, but rather 3D cultures of human brain cells. They can help us understand certain aspects of brain disorders, but their understanding is limited. This technology is a significant step forward in understanding brain disorders and has the potential to lead us closer to diagnosing and treating these disorders on a molecular level. Despite our progress in classifying psychiatric disorders, our molecular understanding of them is behind other branches of medicine. The complexity of the brain and the lack of access to living tissue have held us back. Brain organoids offer a new tool to overcome these challenges and bring us closer to a molecular understanding of brain disorders.

    • Revolutionizing Understanding of Psychiatric DisordersRecent advancements in cell engineering enable us to create brain-like tissue from individuals' cells, providing new opportunities for studying complex psychiatric disorders and developing targeted therapies.

      Understanding psychiatric disorders through traditional methods such as postmortem tissue analysis and animal modeling has its limitations. These methods provide limited information and may not accurately represent the complex genetics and molecular machinery behind these disorders. However, recent advancements in cell engineering allow us to obtain pluripotent stem cells from individuals non-invasively, which can then be instructed to become brain-like tissue in a dish. This opens up new opportunities for studying the molecular basis of psychiatric disorders and developing targeted therapies. It's a mind-blowing concept to take a skin or blood cell, turn it into a brain cell, and then watch development start again in a dish. This approach has the potential to revolutionize our understanding and treatment of complex psychiatric disorders.

    • 3D lab culture for neural cells3D lab culture extends neural cell survival and self-organization, potentially advancing neurological research and treatments

      Researchers have discovered that when growing neural cells in a lab, keeping them in a three-dimensional culture instead of a flat dish allows them to survive and develop for much longer periods of time. This is significant because it enables the cells to self-organize and progress through different stages of development, similar to how the human brain develops in the womb. The innovation came from realizing that if cells cannot attach to the dish, they form a wall of cells that can fuel each other, allowing for long-term survival. This breakthrough has the potential to advance our understanding of neural development and potentially lead to new treatments for neurological conditions. Essentially, this research is replicating the natural process of development in a lab setting, allowing us to study the complexities of the brain and its evolution in a new way.

    • Understanding Brain Disorders through Complex Brain ModelsResearchers create brain organoids to study brain disorders, revealing sequential cell generation, astrocyte maturation, and surprising discoveries, potentially leading to new treatments.

      Researchers are developing complex models of the human brain using three-dimensional cell cultures, often referred to as brain organoids or mini-brains. These models help scientists understand various brain disorders that may not be present in lower animal brains. The term "organoid" is a broad one, encompassing various three-dimensional cell cultures, including those derived from patients' biopsies. While these brain organoids do recapitulate some aspects of brain function, they do not fully replicate the complexity of the human brain. Some brain regions, like the cerebral cortex, are easier to create than others. These models offer valuable insights, such as the sequential generation of cell types and the maturation of astrocytes, which are crucial for neurons to form synapses. The long-term maintenance of these organoids has led to surprising discoveries, like the cells' ability to recognize maturation time points and even the onset of "birth." These findings provide essential information for understanding brain disorders and could potentially lead to new treatments.

    • The intricate process of brain development from prenatal to postnatal lifeBrain development is a gradual process that occurs from prenatal to postnatal life, involving key cellular components like astrocytes and the balance between excitation and inhibition. New insights into previously inaccessible stages of brain development can lead to advancements in understanding neurological disorders and potential treatments.

      The development of the human brain is a robust and intricate process that begins well before birth and continues into postnatal life. The maturation of the brain is not solely dependent on the birth itself, but rather on the gradual transition of key cellular components like astrocytes. This process is not sudden but rather a slow progression that can be observed at the gene expression, chromatin, and epigenetic levels. The parallels between this process and the development of seeds into plants are striking. The greatest opportunity for scientific advancement lies in accessing previously inaccessible stages of brain development, which are likely related to various diseases. For instance, the balance between excitation and inhibition in the human cortex is crucial for normal brain function. Disruptions to this balance have been linked to conditions such as epilepsy and autism. Interestingly, inhibitory cortical neurons, which play a crucial role in regulating this balance, are not born in the cortex but rather in another part of the brain called MGE. These neurons then migrate to the cortex, moving in a peculiar way that involves the nucleus being pulled up by a muscle-like contraction. This process occurs every few hours, highlighting the intricacy and precision of brain development. Understanding these mechanisms can provide valuable insights into the causes of neurological disorders and potentially lead to new treatments.

    • Studying brain development through fusion of excitatory and inhibitory neuronsResearchers study brain development by growing separate organoids for excitatory and inhibitory neurons, then fusing and observing their migration and synapse formation, providing insights into neurological disorders like Timothy Syndrome.

      The development of the brain involves the movement and fusion of different types of neurons, which is a complex process that continues into the second year of life in humans. This process, called neurogenesis, is crucial for the proper functioning of the brain, and disruptions in it have been linked to conditions like autism and epilepsy. Researchers have developed a model in a lab dish to study this process, where they grow separate organoids for excitatory and inhibitory neurons, and then fuse them together. The inhibitory neurons then migrate towards the other side and start making synapses with excitatory neurons, leading to energy transmission and the formation of complex neural structures. Interestingly, a rare condition called Timothy Syndrome, caused by a single gene mutation, affects the migration of neurons, providing insight into the importance of this process in brain development and potential links to neurological disorders.

    • Learning from lab-grown brain organoids despite limitationsUnderstanding molecular mechanisms behind brain development timeline could potentially lead to ways to accelerate or decelerate it. Brain organoids recapitulate human brain's slower development process, providing insights into neoteny and social learning.

      Lab-grown brain organoids offer valuable insights into the intricacies of brain development, but they come with limitations such as long culture times. However, these limitations also present opportunities for further research, as understanding the molecular mechanisms behind the developmental timeline could potentially lead to ways to accelerate or decelerate it. The human brain's slower development, a result of neoteny, is believed to allow for more extensive social learning. Brain organoids recapitulate this process in vitro, and figuring out the molecular mechanisms behind it could unlock new levels of understanding. It's important to remember that these models are not perfect replicas of the brain but rather useful tools to answer specific questions related to brain development and diseases.

    • Modeling neurodevelopmental disorders with 3D brain organoids3D brain organoids can help study neurodevelopmental disorders at the molecular level, despite limitations, and pave the way for defining these disorders biologically, ultimately leading to new treatments.

      While the current 3D brain organoid models have limitations, such as the absence of vascularization and certain immune cells, they can still be useful in studying neurodevelopmental disorders. These disorders, which arise due to abnormal brain development, can be effectively modeled at the molecular level. Although it may be more challenging to study neurodegenerative disorders or disorders with later onset, such as Alzheimer's disease, there is potential for studying genetic forms of complex disorders like schizophrenia. The ultimate goal is to define these disorders biologically, moving away from their behavioral definitions, and to accept that they are groups of disorders rather than single diseases. The future of this field lies in engineering and refining these models, building upon past successes, and pushing the boundaries of what is possible. This engineering approach shares similarities with the process of designing and building complex systems, making it a promising avenue for understanding and treating various brain disorders.

    • Reverse engineering biology for disease modelingAdvancements in biology include creating organoids, but ethical concerns arise from potential transplantations and sensory input in animals

      The field of biology, particularly in relation to disease modeling and engineering, has shifted towards reverse engineering and assembling "working blocks" to understand complex systems. This approach has led to significant advancements, including the creation of organoids that can form connections and small circuits. However, these structures are not miniature versions of the human brain and lack sensory experience, which is crucial for brain development. Ethical concerns mainly arise from potential transplantations into animals, where the organoids may receive sensory input and participate in circuit functions. As we continue to develop more advanced models to better understand psychiatric disorders, it's important to consider the ethical implications and ensure that these models closely resemble the human brain.

    • Exploring the potential of brain chips: Scientific and ethical questionsBrain chips made of living neurons raise scientific and ethical questions about their potential applications, limitations, and ethical implications, including consciousness, human uniqueness, and implications for psychiatry and molecular psychiatry.

      The development of brain chips, made up of living neurons, raises both scientific and ethical questions. These questions revolve around the potential applications and limitations of this technology, as well as the legal and ethical implications of creating biological computing devices. The long-term implications of this technology are vast, with potential applications in scientific discovery, disease treatment, and even creating more complex networks that could be used as computing devices. However, as we move towards building more complex circuits and potentially even transplanting these chips into humans, ethical concerns around consciousness, human uniqueness, and the implications for psychiatry and molecular psychiatry will need to be addressed. The next steps in this field include applying the technology more broadly and understanding the human brain's unique biology and computing capabilities. Ultimately, this technology could lead to a deeper understanding of consciousness and the nature of the human brain. It's an exciting time as we explore the potential of this new tool and the possibilities it holds for both scientific discovery and ethical dilemmas.

    • Understanding the brain and intelligence at an exciting intersectionNeuroscience research connections will have far-reaching implications for education, technology, and healthcare

      Neuroscience is at an exciting juncture, sitting at the intersection of understanding the brain, intelligence, learning, and both macro and micro scales. This intersection holds significant potential for various disciplines in the years to come. The connections being made and discovered in neuroscience research will likely have far-reaching implications for fields such as education, technology, and healthcare. As we continue to explore the complexities of the brain and intelligence, the insights gained will undoubtedly lead to new discoveries and innovations. Thank you for tuning into the a16z podcast, and for having me on the show to discuss this fascinating topic.

    Recent Episodes from a16z Podcast

    Cybersecurity's Past, Present, and AI-Driven Future

    Cybersecurity's Past, Present, and AI-Driven Future

    Is it time to hand over cybersecurity to machines amidst the exponential rise in cyber threats and breaches?

    We trace the evolution of cybersecurity from minimal measures in 1995 to today's overwhelmed DevSecOps. Travis McPeak, CEO and Co-founder of Resourcely, kicks off our discussion by discussing the historical shifts in the industry. Kevin Tian, CEO and Founder of Doppel, highlights the rise of AI-driven threats and deepfake campaigns. Feross Aboukhadijeh, CEO and Founder of Socket, provides insights into sophisticated attacks like the XZ Utils incident. Andrej Safundzic, CEO and Founder of Lumos, discusses the future of autonomous security systems and their impact on startups.

    Recorded at a16z's Campfire Sessions, these top security experts share the real challenges they face and emphasize the need for a new approach. 

    Resources: 

    Find Travis McPeak on Twitter: https://x.com/travismcpeak

    Find Kevin Tian on Twitter: https://twitter.com/kevintian00

    Find Feross Aboukhadijeh on Twitter: https://x.com/feross

    Find Andrej Safundzic on Twitter: https://x.com/andrejsafundzic

     

    Stay Updated: 

    Find a16z on Twitter: https://twitter.com/a16z

    Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

    Subscribe on your favorite podcast app: https://a16z.simplecast.com/

    Follow our host: https://twitter.com/stephsmithio

    Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

     

    The Science and Supply of GLP-1s

    The Science and Supply of GLP-1s

    Brooke Boyarsky Pratt, founder and CEO of knownwell, joins Vineeta Agarwala, general partner at a16z Bio + Health.

    Together, they talk about the value of obesity medicine practitioners, patient-centric medical homes, and how Brooke believes the metabolic health space will evolve over time.

    This is the second episode in Raising Health’s series on the science and supply of GLP-1s. Listen to last week's episode to hear from Carolyn Jasik, Chief Medical Officer at Omada Health, on GLP-1s from a clinical perspective.

     

    Listen to more from Raising Health’s series on GLP-1s:

    The science of satiety: https://raisinghealth.simplecast.com/episodes/the-science-and-supply-of-glp-1s-with-carolyn-jasik

    Payers, providers and pricing: https://raisinghealth.simplecast.com/episodes/the-science-and-supply-of-glp-1s-with-chronis-manolis

     

    Stay Updated: 

    Let us know what you think: https://ratethispodcast.com/a16z

    Find a16z on Twitter: https://twitter.com/a16z

    Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

    Subscribe on your favorite podcast app: https://a16z.simplecast.com/

    Follow our host: https://twitter.com/stephsmithio

    Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

    The State of AI with Marc & Ben

    The State of AI with Marc & Ben

    In this latest episode on the State of AI, Ben and Marc discuss how small AI startups can compete with Big Tech’s massive compute and data scale advantages, reveal why data is overrated as a sellable asset, and unpack all the ways the AI boom compares to the internet boom.

     

    Subscribe to the Ben & Marc podcast: https://link.chtbl.com/benandmarc

     

    Stay Updated: 

    Let us know what you think: https://ratethispodcast.com/a16z

    Find a16z on Twitter: https://twitter.com/a16z

    Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

    Subscribe on your favorite podcast app: https://a16z.simplecast.com/

    Follow our host: https://twitter.com/stephsmithio

    Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

    Predicting Revenue in Usage-based Pricing

    Predicting Revenue in Usage-based Pricing

    Over the past decade, usage-based pricing has soared in popularity. Why? Because it aligns cost with value, letting customers pay only for what they use. But, that flexibility is not without issues - especially when it comes to predicting revenue. Fortunately, with the right process and infrastructure, your usage-based revenue can become more predictable than the traditional seat-based SaaS model. 

    In this episode from the a16z Growth team, Fivetran’s VP of Strategy and Operations Travis Ferber and Alchemy’s Head of Sales Dan Burrill join a16z Growth’s Revenue Operations Partner Mark Regan. Together, they discuss the art of generating reliable usage-based revenue. They share tips for avoiding common pitfalls when implementing this pricing model - including how to nail sales forecasting, adopting the best tools to track usage, and deal with the initial lack of customer data. 

    Resources: 

    Learn more about pricing, packaging, and monetization strategies: a16z.com/pricing-packaging

    Find Dan on Twitter: https://twitter.com/BurrillDaniel

    Find Travis on LinkedIn: https://www.linkedin.com/in/travisferber

    Find Mark on LinkedIn: https://www.linkedin.com/in/mregan178

    Stay Updated: 

    Let us know what you think: https://ratethispodcast.com/a16z

    Find a16z on Twitter: https://twitter.com/a16z

    Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

    Subscribe on your favorite podcast app: https://a16z.simplecast.com/

    Follow our host: https://twitter.com/stephsmithio

    Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

    California's Senate Bill 1047: What You Need to Know

    California's Senate Bill 1047: What You Need to Know

    On May 21, the California Senate passed bill 1047.

    This bill – which sets out to regulate AI at the model level – wasn’t garnering much attention, until it slid through an overwhelming bipartisan vote of 32 to 1 and is now queued for an assembly vote in August that would cement it into law. In this episode, a16z General Partner Anjney Midha and Venture Editor Derrick Harris breakdown everything the tech community needs to know about SB-1047.

    This bill really is the tip of the iceberg, with over 600 new pieces of AI legislation swirling in the United States. So if you care about one of the most important technologies of our generation and America’s ability to continue leading the charge here, we encourage you to read the bill and spread the word.

    Read the bill: https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202320240SB1047

    a16z Podcast
    enJune 06, 2024

    The GenAI 100: The Apps that Stick

    The GenAI 100: The Apps that Stick

    Consumer AI is moving fast, so who's leading the charge? 

    a16z Consumer Partners Olivia Moore and Bryan Kim discuss our GenAI 100 list and what it takes for an AI model to stand out and dominate the market.

    They discuss how these cutting-edge apps are connecting with their users and debate whether traditional strategies like paid acquisition and network effects are still effective. We're going beyond rankings to explore pivotal benchmarks like D7 retention and introduce metrics that define today's AI market.

    Note: This episode was recorded prior to OpenAI's Spring update. Catch our latest insights in the previous episode to stay ahead!

     

    Resources:

    Link to the Gen AI 100: https://a16z.com/100-gen-ai-apps

    Find Bryan on Twitter: https://twitter.com/kirbyman

    Find Olivia on Twitter: https://x.com/omooretweets

     

    Stay Updated: 

    Find a16z on Twitter: https://twitter.com/a16z

    Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

    Subscribe on your favorite podcast app: https://a16z.simplecast.com/

    Follow our host: https://twitter.com/stephsmithio

    Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

    Finding a Single Source of AI Truth With Marty Chavez From Sixth Street

    Finding a Single Source of AI Truth With Marty Chavez From Sixth Street

    a16z General Partner David Haber talks with Marty Chavez, vice chairman and partner at Sixth Street Partners, about the foundational role he’s had in merging technology and finance throughout his career, and the magical promises and regulatory pitfalls of AI.

    This episode is taken from “In the Vault”, a new audio podcast series by the a16z Fintech team. Each episode features the most influential figures in financial services to explore key trends impacting the industry and the pressing innovations that will shape our future. 

     

    Resources: 
    Listen to more of In the Vault: https://a16z.com/podcasts/a16z-live

    Find Marty on X: https://twitter.com/rmartinchavez

    Find David on X: https://twitter.com/dhaber

     

    Stay Updated: 

    Find a16z on Twitter: https://twitter.com/a16z

    Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

    Subscribe on your favorite podcast app: https://a16z.simplecast.com/

    Follow our host: https://twitter.com/stephsmithio

    Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

    A Big Week in AI: GPT-4o & Gemini Find Their Voice

    A Big Week in AI: GPT-4o & Gemini Find Their Voice

    This was a big week in the world of AI, with both OpenAI and Google dropping significant updates. So big that we decided to break things down in a new format with our Consumer partners Bryan Kim and Justine Moore. We discuss the multi-modal companions that have found their voice, but also why not all audio is the same, and why several nuances like speed and personality really matter.

     

    Resources:

    OpenAI’s Spring announcement: https://openai.com/index/hello-gpt-4o/

    Google I/O announcements: https://blog.google/technology/ai/google-io-2024-100-announcements/

     

    Stay Updated: 

    Let us know what you think: https://ratethispodcast.com/a16z

    Find a16z on Twitter: https://twitter.com/a16z

    Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

    Subscribe on your favorite podcast app: https://a16z.simplecast.com/

    Follow our host: https://twitter.com/stephsmithio

    Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

     

     

    Remaking the UI for AI

    Remaking the UI for AI

    Make sure to check out our new AI + a16z feed: https://link.chtbl.com/aiplusa16z
     

    a16z General Partner Anjney Midha joins the podcast to discuss what's happening with hardware for artificial intelligence. Nvidia might have cornered the market on training workloads for now, but he believes there's a big opportunity at the inference layer — especially for wearable or similar devices that can become a natural part of our everyday interactions. 

    Here's one small passage that speaks to his larger thesis on where we're heading:

    "I think why we're seeing so many developers flock to Ollama is because there is a lot of demand from consumers to interact with language models in private ways. And that means that they're going to have to figure out how to get the models to run locally without ever leaving without ever the user's context, and data leaving the user's device. And that's going to result, I think, in a renaissance of new kinds of chips that are capable of handling massive workloads of inference on device.

    "We are yet to see those unlocked, but the good news is that open source models are phenomenal at unlocking efficiency.  The open source language model ecosystem is just so ravenous."

    More from Anjney:

    The Quest for AGI: Q*, Self-Play, and Synthetic Data

    Making the Most of Open Source AI

    Safety in Numbers: Keeping AI Open

    Investing in Luma AI

    Follow everyone on X:

    Anjney Midha

    Derrick Harris

    Check out everything a16z is doing with artificial intelligence here, including articles, projects, and more podcasts.

     

    Stay Updated: 

    Find a16z on Twitter: https://twitter.com/a16z

    Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

    Subscribe on your favorite podcast app: https://a16z.simplecast.com/

    Follow our host: https://twitter.com/stephsmithio

    Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

    a16z Podcast
    enMay 16, 2024

    How Discord Became a Developer Platform

    How Discord Became a Developer Platform

    In 2009 Discord cofounder and CEO, Jason Citron, started building tools and infrastructure for games. Fast forward to today and the platform has over 200 million monthly active users. 

    In this episode, Jason, alongside a16z General Partner Anjney Midha—who merged his company Ubiquiti 6 with Discord in 2021—shares insights on the nuances of community-driven product development, the shift from gamer to developer, and Discord’s longstanding commitment to platform extensibility. 

    Now, with Discord's recent release of embeddable apps, what can we expect now that it's easier than ever for developers to build? 

    Resources: 

    Find Jason on Twitter: https://twitter.com/jasoncitron

    Find Anjney on Twitter: https://twitter.com/AnjneyMidha

     

    Stay Updated: 

    Find a16z on Twitter: https://twitter.com/a16z

    Find a16z on LinkedIn: https://www.linkedin.com/company/a16z

    Subscribe on your favorite podcast app: https://a16z.simplecast.com/

    Follow our host: https://twitter.com/stephsmithio

    Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

     

    Related Episodes

    The Biology of Brain Organoids (or, Don't Call it a Brain in a Dish!)

    The Biology of Brain Organoids (or, Don't Call it a Brain in a Dish!)

    For more on brain organoids and their many applications, check out this episode of Journal Club: "Modeling Mysterious Brain Structures." Host Lauren Richardson talks to Dr. Madeline Lancaster, a Group Leader at the MRC Laboratory of Molecular Biology in Cambridge, about her lab's article in Science describing an organoid model for studying the cerebrospinal fluid and the choroid plexus, and how these organoids can be used to study brain development, evolution, and improve the drug development process.

    Mind Reading Technology

    Mind Reading Technology

    Is mind reading technology fact or fiction? Is it plausible that it could be mainstream within the next few years, and available to everyday consumers?
    What ramifications could this have on humanity? Who is behind technology like this?
    Find out in this episode of the free thinking human.
    brought to you by thefreethinkinghuman.com Please help us grow by sharing our content.
    Contact Us!
    host@thefreethinkinghuman.com
    Twitter
    Instagram
    Music from https://filmmusic.io
    "Slow Burn" by Kevin MacLeod (https://incompetech.com)
    License: CC BY (http://creativecommons.org/licenses/by/4.0/)

    185 - Metabolic Changes, Hemodynamics and EEG in Alzheimer's Disease: June 2021

    185 - Metabolic Changes, Hemodynamics and EEG in Alzheimer's Disease: June 2021

    In this shorter episode, Judy goes over papers published in June 2021 that focus on diagnostic tools of Alzheimer's disease. Topics include metabolic changes, hemodynamics and EEG biomarkers. Listen in to find out more!  

    Sections in this episode:  

    Metabolic changes in AD (1:20)  

    Hemodynamics (9:30)  

    EEG (13:30) 


     

    -------------------------------------------------------------- 

    You can find the numbered bibliography for this episode by clicking here, or the link below:

    https://drive.google.com/file/d/1lzkStThvq02V_tpeuqBDfmZuLlhg6RwQ/view?usp=sharing

    To access the folder with all the bibliographies for 2021 so far, follow this link (it will be updated as we publish episodes and process bibliographies), or click the following link below:

    https://drive.google.com/drive/folders/1N1zx_itPkCDNYE1yFGZzQxDDR-NiRx3p?usp=sharing

    You can also join our mailing list to receive a newsletter by filling this form. 

    Or tweet at us: @AMiNDR_podcast  

    --------------------------------------------------------------

    Follow-up on social media for more updates!

    Facebook:  AMiNDR  

    Twitter: @AMiNDR_podcast

    Instagram: @AMiNDR.podcast

    Youtube: AMiNDR Podcast

    LinkedIn: AMiNDR Podcast

    If you have any questions or concerns, do not hesitate to contact us at: amindrpodcast@gmail.com  

    -------------------------------------------------------------- 

    Please help us by spreading the word about AMiNDR to your friends, colleagues, and networks! Another way you can help us reach more researchers is by leaving us a review on Apple Podcasts or wherever you listen to podcasts. 

    We would like to thank our amazing team for all of the work that goes into every episode of AMiNDR. Today's episode was scripted and hosted by Judy Cheng, edited by Alexandra Pavel, and reviewed by Alexandra Pavel and Anusha Kamesh. The bibliography was created by Jacques Ferreira and wordcloud (wordart.com) generated by Sarah Louadi. 

    Big thanks to the sorting team for sorting all the papers published in June into themes for our episodes: Jacques Ferreira, Elyn Rowe, Ellen Koch, Christy Yu, Nicole Corso, Sarah Louadi, and Naila Kuhlmann. 

    Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, and Jacques Ferreira, for keeping everything running smoothly.

    Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   

    https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   

    -------------------------------------------------------------- 

    If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, creating bibliographies, and promotions. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  

    --------------------------------------------------------------

    *About AMiNDR: *  

    Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!" 

    190 - Brain Connectivity Changes in Alzheimer's Disease: June 2021

    190 - Brain Connectivity Changes in Alzheimer's Disease: June 2021

    Interested in brain connectivity changes specific to Alzheimer's disease? Come join us as Judy presents 13 papers featuring fMRI, machine learning and other brain mapping techniques that explore functional connectivity in AD. You're sure to learn something new!  

    Sections in this episode:  

    fMRI (01:32)  

    Machine Learning (12:10)  

    Other (14:36) 


     

    -------------------------------------------------------------- 

    You can find the numbered bibliography for this episode by clicking here, or the link below:

    https://drive.google.com/file/d/1qQcxhvhiOUvDSfqcLh4FbI43oFEEelrm/view?usp=sharing

    To access the folder with all the bibliographies for 2021 so far, follow this link (it will be updated as we publish episodes and process bibliographies), or click the following link below:

    https://drive.google.com/drive/folders/1N1zx_itPkCDNYE1yFGZzQxDDR-NiRx3p?usp=sharing

    You can also join our mailing list to receive a newsletter by filling this form. 

    Or tweet at us: @AMiNDR_podcast  

    --------------------------------------------------------------

    Follow-up on social media for more updates!

    Facebook:  AMiNDR  

    Twitter: @AMiNDR_podcast

    Instagram: @AMiNDR.podcast

    Youtube: AMiNDR Podcast

    LinkedIn: AMiNDR Podcast

    If you have any questions or concerns, do not hesitate to contact us at: amindrpodcast@gmail.com  

    -------------------------------------------------------------- 

    Please help us by spreading the word about AMiNDR to your friends, colleagues, and networks! Another way you can help us reach more researchers is by leaving us a review on Apple Podcasts or wherever you listen to podcasts. 

    We would like to thank our amazing team for all of the work that goes into every episode of AMiNDR. Today's episode was scripted and hosted by Judy Cheng, edited by Lara Onbasi, and reviewed by Ellen Koch. The bibliography was created by Jacques Ferreira and the wordcloud (wordart.com) was generated by Sarah Louadi. 

    Big thanks to the sorting team for sorting all the papers published in June into themes for our episodes: Jacques Ferreira, Elyn Rowe, Ellen Koch, Christy Yu, Nicole Corso, Sarah Louadi, and Naila Kuhlmann. 

    Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, and Jacques Ferreira, for keeping everything running smoothly.

    Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.   

    https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w   

    -------------------------------------------------------------- 

    If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, creating bibliographies, and promotions. However, if you are interested in helping in other ways, don't hesitate to apply anyways.  

    --------------------------------------------------------------

    *About AMiNDR: *  

    Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!" 

    David Eagleman (Stanford School of Medicine) - A Brainy Approach to Innovation

    David Eagleman (Stanford School of Medicine) - A Brainy Approach to Innovation
    Renowned neuroscientist David Eagleman shares his passion for translating the complexities of cognition into mind-blowing inventions and educational material for the masses. The public-television host, bestselling author and Stanford adjunct professor speaks with Tina Seelig of the Stanford Technology Ventures Program about his decision to leave the lab and dedicate his life to bringing scientific discoveries into the world.